P1-17-3 - Chemotherapy with Cisplatin and Pemetrexed for Non-Small Cell Lung Cancer Patients: a Retrospective Single Center Study

Abstract

Background: Cisplatin and pemetrexed combination regimen (CP) is one of the promising therapies for non-squamous NSCLC patients. The PARAMOUT trial demonstarated the survival benefits of continuation maintenance chemotherapy with pemetrexed (PEM) after four cycles of CP. In Japan, only one phase II study showed feasibility and effectiveness of CP therapy.Methods: Japanese advanced NSCLC patients who were administered CP in National Kyushu Cancer Center from 2009 to 2014 were enrolled in this retrospective study. The drugs were administered day1 every three weeks as a cycle. Treatment was repeated four to six cycles until disease progression or unacceptable toxicities. Non-PD patients received maintenance chemotherapy with pemetrexed until disease progression. The response rate of CP was evaluated retrospectively.Results: One hundred and six patients received CP treatment. Sixty six patients were male and 40 were female. Median age was 63 years (range 34-77). Pathological diagnosis was adenocarcinoma in 104, large cell carcinoma in 1 and NSCLC in 2. The clinical stage of patients was IIIA in 1, IIIB in 3, IV in 86 and postoperative recurrence was 16. ECOG performance status was 0 in 58 patients, 1 in 46 patients and 2 in 2 patients. EGFR mutation is positive in 31, negative in 68, and unknown in 7, respectively. The median cycles of induction chemotherapy were 4. Thirty nine patients (36.8%) had partial response, 44 patients (41.5%) had stable disease. The median progression-free survival from the initiation of induction chemotherapy was 163 days.Conclusions: CP combination therapy for Japanese non-squamous NSCLC patients is feasible. Effectiveness of this regimen in current study is equivalent to previous clinical trials. Further prospective studies are warranted.